The seven SCGs in this pathway are lecithin retinol acyltransferase (LRAT), retinoid isomerase (RPE65), three retinol dehydrogenases (RDH5, RDH10 and RDH11), beta‐carotene oxygenase 1 (BCO1) and a retinaldehyde dehydrogenase 3 (ALDH1A3) (Table 1).

May 4, 2018 · Retinol dehydrogenase 11 (RDH11) is a microsomal short-chain dehydrogenase/reductase that recognizes all- trans - and cis -retinoids as substrates and prefers NADPH as a cofactor. Previous work has suggested that RDH11 contributes to the oxidation of 11-<i>cis</i>-retinol to 11-<i>cis</i> …

Dec 21, 2021 · Mass spectrometry-based cellular thermal shift analysis reveals that ALDH1A3 is the primary binding protein for MCI-INI-3 in MES GSC lysates. The inhibitory effect of MCI-INI-3 on retinoic acid...

Retinal reductases (Dhrs3, Dhrs4, Rdh11) reduce retinal into retinol, thereby restraining ATRA biosynthesis. Retinal dehydrogenases (Raldh1, 2, 3) dehydrogenate retinal irreversibly into ATRA. ATRA regulates its own concentrations by inducing Lrat and ATRA degradative enzymes.

We employ a three-step developmental model to examine effects of Cyp1b1 and retinol on postnatal liver lipogenesis. Importantly, we show that Rdh11 and Aldh1a1, genes that appreciably determine liver retinaldehyde fate, fit within this network.

Oct 19, 2016 · Here we report the first crystal structure of human ALDH1A3 complexed with NAD + and the product all- trans retinoic acid (REA). The tetrameric ALDH1A3 folds into a three domain-based...

Retinol dehydrogenase 11 (RDH11) is a microsomal short-chain dehydrogenase/reductase that recognizes all-trans– and cis–retinoids as substrates and prefers NADPH as a cofactor.

ALDH1a3 is established as a primary marker of failing beta cells in the pancreas, both in human type 2 diabetes patients [18] and mouse models of diabetes. [19] ALDH1a3 expression has been shown to suppress insulin secretion and increase glucagon production in …

rdh11 Retinol dehydrogenase 11; Retinol dehydrogenase with a clear preference for NADP. Displays high activity towards 9-cis, 11-cis and all-trans-retinol, and to a lesser extent on 13-cis-retinol.

WIN 18,446 is a potent reversible inhibitor of ALDH1A1 and ALDH1A3 and a time dependent inhibitor (TDI) of ALDH1A2 [34]. Due to its broad and potent ALDH1A inhibition, it provides a unique, novel tool to alter ALDH1A activity in vivo and to test the tissue specific effects of ALDH1A inhibition to at RA concentrations.